Research progress on the lipid-lowering mechanisms and clinical application of GLP-1 receptor agonists
- VernacularTitle:GLP-1受体激动剂降脂作用机制及临床应用的研究进展
- Author:
Yanjiao ZHU
1
;
Rui GAO
1
;
Huiying ZONG
2
;
An’an LI
2
;
Penglin ZHOU
2
;
Shuai HE
2
;
Xichao WU
2
;
Yan LI
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital）/Shandong Engineering and Technology Research Center for Clinical Evaluation and Development of Pediatric Drugs/Shandong Medicine and Health Key Laboratory of Clinical Pharmacy，Jinan 250014，China
2. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355，China
- Publication Type:Journal Article
- Keywords:
GLP-1 receptor agonists;
lipid-lowering effect;
mechanism;
clinical research;
liraglutide;
semaglutide
- From:
China Pharmacy
2025;36(20):2615-2620
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide-1 （GLP-1） receptor agonists are a novel class of antidiabetic drugs that also possess lipid- lowering and cardiovascular protective effects， with liraglutide and semaglutide being their representative medications. Based on a systematic literature search， this review summarizes the lipid-lowering mechanisms by which liraglutide and semaglutide exert direct effects on the liver and kidney （regulating autophagy， key lipid metabolism pathways， reverse cholesterol transport， etc.）， direct actions on adipose tissue （affecting adipocyte proliferation and differentiation， expression of lipid metabolism proteins， and gene transcription）， activation of sympathetic pathways through the central nervous system， and modulation of the gut microbiota. Additionally， it summarizes the clinical evidence of their lipid-lowering effects in populations with type 2 diabetes mellitus， overweight individuals， and others. These findings indicate that GLP-1 receptor agonists exert lipid-lowering effects by acting on multiple tissues or systems， providing crucial evidence for further elucidating the molecular mechanisms of these drugs in lipid regulation and exploring potential new ideas for their clinical applications.
